Vyvgart Hytrulo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis of generalized myasthenia gravis, expansion of biologic autoimmune treatments, availability of IV biologic alternatives, rising demand for chronic disease management solutions, improved specialist access.

The growth in the forecast period can be attributed to increasing adoption of subcutaneous biologics, expansion into additional autoimmune indications, rising investments in neurology-focused therapies, growing preference for non-infusion treatments, continued innovation in antibody-based drugs. Major trends in the forecast period include increasing adoption of subcutaneous biologic formulations, rising demand for convenient autoimmune therapies, growing focus on fcrn inhibitor treatments, expansion of home and outpatient administration models, enhanced emphasis on patient convenience and compliance.

The rising prevalence of autoimmune disorders is expected to drive growth in the Vyvgart Hytrulo market. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own healthy cells and tissues, viewing them as harmful. The increasing prevalence of these conditions is linked to genetic predisposition, environmental factors, infections, and lifestyle changes, including diet and higher chemical exposure. Vyvgart Hytrulo is used to treat autoimmune diseases, particularly generalized myasthenia gravis (gMG), by lowering pathogenic antibodies through inhibition of the neonatal Fc receptor (FcRn). For example, in August 2024, the Myasthenia Gravis Foundation of America, a US-based organization, reported that myasthenia gravis affects approximately 150 to 200 individuals per million people worldwide, with around 37 per 100,000 people affected in the United States. Therefore, the rising prevalence of autoimmune disorders is propelling the Vyvgart Hytrulo market.

The growing focus on personalized medicine is also expected to support the Vyvgart Hytrulo market. Personalized medicine tailors treatment plans to an individual’s genetic makeup, lifestyle, and environment to achieve more effective outcomes. This approach is gaining momentum due to advancements in genomics, technology, and data analytics, alongside increasing demand for precise and tailored therapies. Vyvgart Hytrulo exemplifies personalized medicine by specifically targeting autoimmune mechanisms in patients with generalized myasthenia gravis who are positive for anti-AChR antibodies. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the increasing emphasis on personalized medicine is driving the Vyvgart Hytrulo market.

A key trend in the Vyvgart Hytrulo market is the advancement of targeted therapy, providing flexible and effective treatment options for gMG patients. Targeted therapy focuses on molecules involved in disease progression, minimizing damage to healthy cells. In June 2023, argenx SE, a Netherlands-based immunology company, received FDA approval for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous use in treating gMG. This approval offers patients the convenience of a subcutaneous injection, with efficacy comparable to the intravenous form, reducing anti-AChR antibody levels while maintaining a favorable safety profile. The subcutaneous option allows administration in multiple settings, such as infusion centers or at home, enhancing patient convenience, adherence, and overall quality of care.

Major companies operating in the vyvgart hytrulo market are Argenx SE.

North America was the largest region in the vyvgart hytrulo market in 2025. The regions covered in the vyvgart hytrulo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vyvgart hytrulo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the vyvgart hytrulo market by increasing costs associated with imported monoclonal antibody inputs, specialized formulation technologies, injection delivery systems, and cold-chain logistics. Neurology clinics and specialty hospitals in North America and Europe are most affected due to reliance on international biologics supply chains, while Asia-Pacific experiences cost pressures related to biologic imports and storage. These tariffs are raising treatment costs and influencing pricing strategies. However, they are also encouraging regional biologics manufacturing expansion, localized fill-and-finish operations, and long-term investments in domestic autoimmune therapy production.

The vyvgart hytrulo market research report is one of a series of new reports that provides vyvgart hytrulo market statistics, including vyvgart hytrulo industry global market size, regional shares, competitors with a vyvgart hytrulo market share, detailed vyvgart hytrulo market segments, market trends and opportunities, and any further data you may need to thrive in the vyvgart hytrulo industry. This vyvgart hytrulo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

VYVGART Hytrulo is a subcutaneous formulation of Vyvgart (efgartigimod alfa-fcab), developed for the treatment of generalized myasthenia gravis (gMG) in adults who are positive for anti-acetylcholine receptor (AChR) antibodies. Administered via injection under the skin, it provides a convenient and less time-consuming alternative to the intravenous version.

The main formulations of Vyvgart Hytrulo are intravenous (IV) and subcutaneous (SC). Intravenous administration delivers the medication directly into the bloodstream, offering controlled therapeutic effects, while subcutaneous administration allows for easier, at-home use. It is indicated for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The end users include adult and geriatric patients, with distribution through hospital pharmacies, retail pharmacies, and online pharmacies.

The vyvgart hytrulo market consists of sales of injections and solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.